Early assessment of therapeutic efficacy in lymphoma patients via a blood-based multi-omics response monitoring test.

BMC Cancer · 2025 · PMC12210469 · PMID 40597857

Europe PMC DOI

hedged sentences

0.0540

closest p · 1.1× alpha

0.6500

boldest claim

The sentences

showed a trendP = 0.054so close (0.05 < p ≤ 0.1)

In aggressive B-cell lymphomas, 97.1% (66/68) achieved interim PET/CT response; however, 12 (18.2%) of them were identified as molecular non-responders and showed a trend toward inferior PFS ( P = 0.054, Fig. 4 C).

also in 53,322 other papers

did not reach statistical significanceP = 0.65not close (p > 0.1)

The PFS difference between LDH+ and LDH- groups did not reach statistical significance (HR 1.25, 95% CI 0.48–3.30, P = 0.65, Fig. 2 C), nor did the OS (HR 0.51, 95% CI 0.06–4.22, P = 0.52, Figure S4C).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.